The Distribution Clinical and Demographic Features of HBsAg Positive Patients in Şanlıurfa Region

Abstract

ÖZObjective: The objective of this study was to investigate the distribution of the clinic and demographic characteristics of hepatitis b surface antigen (HBsAg) positive patients in Şanlıurfa region. 49±15 years, range: 20-73) and 24 (83%) were male. Seventeen patients (5%) (mean age: 37.8±12.8 years, range: 16-60) were antihepatitis D virus (anti-HDV) positive, 11 (65%) were male, 5 of them were in the cirrhotic stage. Two patients (0.6%) had HBV/HCV coinfection, two patients (0.6%) had hepatocellular carcinoma (HCC). Seven patients were pregnant, three patients were given tenofovir in the 3 rd trimester, due to high viral load. Seventy one of 73 (26%) patients who were identified to have cirrhosis or chronic hepatitis due to HBV or HDV, 71 of (those who received or completed interferon treatment) received antiviral therapy, most commonly tenofovir. Liver transplantation was performed in two patients (0.6%) due to HBV related liver cirrhosis. Conclusion: Three-quarters HBsAg seropositive patients in Şanlıurfa region were inactive HBV carriers and one quarter were at the stage of chronic hepatitis or cirrhosis. Inactive carriers and chronic hepatitis patients are often in the 3 rd decade and cirrhotic patients were in the 4 th decade of life. Chronic HDV was observed in 5% of patients, HBV related HCC 0.6%, HBV/HCV co-infection was found in 0.6% of patients. Almost all patients with chronic hepatitis or cirrhosis were found to be received or/receiving antiviral treatment and the most commonly used medication was tenofovir.

The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review

“…During the study period of 35 years, 111 publications were found 13–123 . Among inactive HBV carriers, 34 studies reported HDV prevalence and it did not change significantly over three decades 6,13–45 (Table 1).…”

“…Among inactive HBV carriers, 34 studies reported HDV prevalence and it did not change significantly over three decades 6,13–45 (Table 1). Among patients with chronic hepatitis, 50 studies reported decreasing (from Period 1 to Period 2) and then increasing (from Period 2 to period 3) HDV prevalence 9,13–18,20,22–27,29–33,35–65 . (Table 2).…”

“…Special groups were analysed including HBV‐infected cirrhotics 16,39,41,48,53,57,61,66,82–90 : From Period 1 to 2 and 3, the prevalences were 62/385 (16.1%), 179/806 (22.2%) and 29/301 (9.6%), respectively ( p < .00001). Among blood donors found to be HBV‐positive, anti‐HDV was also tested in four studies from 1994 to 2011 and reported 0%–6.9% 91–94 .…”

Acute Viral Hepatitis B with a Severe Clinical Course in Pregnancy: A Case Report

“…Since the risk of resistance is low, tenofovir disoproxil fumarate should be preferred (16). In our series of 296 HBsAg-positive patients whom we followed between Dec 2011 and Apr 2012 in the Şanlıurfa region, there were 7 pregnant patients (approximately 2%), and tenofovir was started in 3 of these patients in the last trimester because of the higher viral load (2). In our patient, severe hepatitis B was considered and tenofovir disoproxil fumarate therapy was started.…”

“…Şanlıurfa is in a HBV endemic region where birth rates increase each year (2). Pregnancy-specific liver diseases are responsible for approximately 60% of the liver diseases in pregnancy, whereas 40% of these diseases are caused by acute viral hepatitis (3,4).…”